Immunohistochemical Evaluation of GATA3 Expression in Patch‐Stage Mycosis Fungoides ( MF ) Compared With Benign Inflammatory Dermatoses ( BID )
Journal of Cutaneous Pathology · 2026-09 · 53 (9) · 824-831
DOI: 10.1111/cup.70117 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Journal of Cutaneous Pathology, online erschienen am 04.05.2026. Verfasst von Fatemeh Montazer und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, Firoozabadi Hospital, School of Medicine, Iran University of Medical Sciences (IUMS), Tehran, Iran. Hauptthemen laut MEDLINE: GATA3 Transcription Factor, Mycosis Fungoides, Skin Neoplasms, Biomarkers, Tumor. Die Arbeit nennt 21 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
The histopathologic distinction between patch‐stage mycosis fungoides (MF) and benign inflammatory dermatoses (BID) remains a persistent diagnostic challenge, often due to overlapping clinical and immunophenotypic features. GATA binding protein 3 (GATA3), a transcription factor critical in T‐helper 2 cell differentiation, has emerged as a potential immunohistochemical marker in T‐cell neoplasms. This study aimed to evaluate GATA3 expression in patch‐stage MF compared with BID to assess its diagnostic value. Sixty formalin‐fixed, paraffin‐embedded skin biopsies were retrospectively analyzed, including 30 cases of patch‐stage MF and 30 cases of BID (psoriasis, chronic dermatitis, and lichen planus). Immunohistochemical staining for GATA3 was performed, and lymphocytic nuclear staining was assessed in dermal and epidermal compartments. GATA3 expression > 50% in dermal lymphocytes was observed in 20% of MF cases and 6.7% of BID cases, yielding high specificity (93.3%) but low sensitivity (20%) for MF diagnosis. Epidermal GATA3 expression was uniformly low across both groups. No significant correlations were found between GATA3 expression and key histopathologic or immunophenotypic features of MF. Although elevated dermal GATA3 expression may support the diagnosis of MF in some cases, its substantial overlap with BID and low sensitivity limit its utility as a reliable standalone diagnostic marker for early‐stage MF. GATA3 can be incorporated into broader immunohistochemical panels alongside more specific markers to improve diagnostic accuracy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pathology, Firoozabadi Hospital, School of Medicine, Iran University of Medical Sciences (IUMS), Tehran, Iran.
- School of Medicine, Mazandaran University of Medical Sciences, Sari, Iran.
- Skin & Stem Cell Research Center, Tehran University of Medical Sciences, Tehran, Iran.
- School of Medicine, Iran University of Medical Sciences (IUMS), Tehran, Iran.
ORCID-Profile: Mohammad Malekan
Zitieren
APA
Montazer, F., Malekan, M., & Abedi, H. (2026). Immunohistochemical Evaluation of GATA3 Expression in Patch‐Stage Mycosis Fungoides ( MF ) Compared With Benign Inflammatory Dermatoses ( BID ). Journal of Cutaneous Pathology, 53(9), 824-831. https://doi.org/10.1111/cup.70117
Vancouver
Montazer F, Malekan M, Abedi H. Immunohistochemical Evaluation of GATA3 Expression in Patch‐Stage Mycosis Fungoides ( MF ) Compared With Benign Inflammatory Dermatoses ( BID ). Journal of Cutaneous Pathology. 2026;53(9):824-831. doi:10.1111/cup.70117
BibTeX
@article{Montazer2026,
author = {Montazer, Fatemeh and Malekan, Mohammad and Abedi, Hamid},
title = {Immunohistochemical Evaluation of GATA3 Expression in Patch‐Stage Mycosis Fungoides ( MF ) Compared With Benign Inflammatory Dermatoses ( BID )},
journal = {Journal of Cutaneous Pathology},
year = {2026},
volume = {53},
number = {9},
pages = {824--831},
doi = {10.1111/cup.70117}
}
EUVIMED